Jun Watanabe（Kinki/Osaka）
We have multiple types of surgical robots (da Vinci Xi, hinotori, and Hugo [available through participation in clinical research]) and provide high-quality robot-assisted surgery by selecting the most suitable system for each patient. The operating surgeon has experience with more than 5,000 surgical cases.
- Specialized area
-
- Robot-assisted surgery for colorectal cancer
Anal-preserving surgery for rectal cancer Detail
- Robot-assisted surgery for colorectal cancer
- surgery
- Robot-assisted surgery for colorectal cancer
Anal-preserving surgery for rectal cancer
- Qualifications/Academia/Position
-
- Doctor of Medicine (PhD)
- Board Certified Surgeon / Instructor, Japan Surgical Society
- Board Certified Surgeon, Japanese Society of Gastroenterological Surgery / Board Certified Gastroenterological Cancer Surgeon / Instructor / Councilor
- Board Certified Endoscopic Surgeon (Colon), Japanese Society for Endoscopic Surgery / Certified Proctor for Robot-assisted Surgery (Colon/Rectum) / Councilor
- Councilor, Japanese Clinical Society of Surgery
- Board Certified Specialist / Instructor / Councilor, Japan Society of Coloproctology
- Certified Oncologist, Japanese Board of Cancer Therapy
- Board Certified Specialist / Instructor, Japan Gastroenterological Endoscopy Society
- Delegate, Japanese Society of Cancer Therapy
- SAGES FUSE (Fundamental Use of Surgical Energy Program) CertifiedCertificate of Hugo Training As a Console Surgeon Mentor site for rectal cancer / colon cancer (Accredited hinotori case observation facility) Certificate of hinotori Training As a Console Surgeon Mentor site for rectal cancer / colon cancer (Accredited da Vinci case observation facility) Certificate of da Vinci System Training As a Console Surgeon
- The Japan Surgical Society (JSS)
- The Japanese Society of Gastroenterological Surgery (JSGS)
- The Japan Society for Endoscopic Surgery (JSES)
- The Japanese Clinical Society of Surgery
- The Japan Society of Coloproctology (JSCP)
- The Japan Gastroenterological Endoscopy Society (JGES)
- The Japanese Society of Gastroenterology (JSGE)
- The Japanese Society of Cancer Therapy
- The Japanese Society of Medical Oncology (JSMO)
- European Society of Coloproctology (ESCP)／European Association for Endoscopic Surgery (EAES)／The Surgical Association for Endo-Laparoscopic Surgeons in the Asia-Pacific (ELSA)
- Affiliated hospital
- Kansai Medical University Hospital
- Website
- https://hp.kmu.ac.jp/
- location
-
〒573-1191
2-3-1 Shinmachi, Hirakata City Google Map Map
- Biography
-
- 2001
- Graduated from Yokohama City University School of Medicine
- 2001
- Toranomon Hospital, Federation of National Public Service Personnel Mutual Aid Associations – Resident, Department of Surgery
- 2003
- Yokosuka Kyosai Hospital, Federation of National Public Service Personnel Mutual Aid Associations – Department of Surgery
- 2004
- Yokohama Municipal Citizen’s Hospital – Department of Surgery
- 2005
- Tokyo Kosei Nenkin Hospital – Department of Surgery
- 2006
- Graduate School of Medicine, Yokohama City University – Department of Gastroenterological Surgery (admission)
- 2006
- RIKEN Genomic Sciences Center – Visiting Researcher
- 2009
- Yokohama Municipal Citizen’s Hospital – Department of Surgery
- 2011
- Yokohama City University School of Medicine – Assistant Professor, Department of Gastroenterological and Oncology Surgery
- 2012
- Yokosuka Kyosai Hospital – Department of Surgery
- 2013
- Yokosuka Kyosai Hospital – Chief Surgeon, Department of Surgery
- 2016
- Yokosuka Kyosai Hospital – Deputy Director, Department of Surgery
- 2017
- Yokohama City University Medical Center – Lecturer, Department of Gastrointestinal Surgery, Gastroenterology Center
- 2021
- Yokohama City University Medical Center – Associate Professor, Department of Gastrointestinal Surgery, Gastroenterology Center
- 2024
- Kansai Medical University – Professor and Chair, Department of Lower Gastrointestinal Surgery
- 2024
- Yokohama City University School of Medicine – Visiting Professor, Department of Gastroenterological and Oncology Surgery
- paper
-
- ctDNA-based molecular residual disease and survival in resectable colorectal cancer Nature Medicine. 2024 Sep. https://doi.org/10.1038/s41591-024-03254-6
- Phase III trial of short-course radiotherapy followed by CAPOXIRI vs. CAPOX in locally advanced rectal cancer: The ENSEMBLE trial ESMO Gastrointestinal Oncology. 2023 In press
- Blood perfusion assessment by indocyanine green fluorescence imaging for minimally invasive rectal cancer surgery (EssentiAL trial): A randomized clinical trial Annals of Surgery. 2023 Online ahead of print
- Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer JAMA. 2023 329(15):1271-1282. doi:10.1001/jama.2023.4428
- Short-term outcomes of a prospective, multicenter, phase 2 trial of total neoadjuvant therapy for locally advanced rectal cancer in JAPAN (ENSEMBLE-1 trial). Annals of Gastroenterological Surgery 2023 July Online First.
- Randomized controlled trial evaluating the effect of the use of a laparoscopic lens cleaning device during laparoscopic colorectal surgery on the multidimensional workload (YCOG1903) Surgical Endoscopy. 2023 Online ahead of print.
- Long-term outcomes of indocyanine green fluorescence-imaging guided laparoscopic lateral pelvic lymph node dissection for clinical stage II/III middle-lower rectal cancer: A propensity score-matched cohort study Techniques in Coloproctology. 2023 Online ahead of print.
- Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance. Int J Clin Oncol. 2022 Oct 28.
- A multicenter cohort study on mapping of lymph node metastasis for splenic flexural colon cancer Annals of Gastroenterological Surgery 2022 Sep Online First.
- Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer - Exploratory sequential examination of acquired mutations in circulating cell-free DNA. Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34184. Online ahead of print.